Drug intelligence / Profile preview

SBC116

Development stage: Preclinical
Lead developer: SapiensBio
Modality: Small Molecules

Overview

SBC116 is a small molecule inhibitor of the Actin-related protein 2/3 complex subunit 2 (ARPC2) currently in preclinical development by SapiensBio. Identified through the company's AI-driven SAPIENTIA platform, SBC116 is an indication expansion of the lead program SBC101. It is designed to treat a broad range of fibrotic conditions, including liver, kidney, cardiac, pancreatic, and skin fibrosis. The mechanism involves inhibiting the Arp2/3 complex, which plays a pivotal role in actin cytoskeleton remodeling and the activation of myofibroblasts. Preclinical studies have confirmed its efficacy in human hepatic stellate cell models, and in vivo evaluations are ongoing to support its development for multi-organ fibrosis.

Targets

ARPC2 (Actin-related protein 2/3 complex subunit 2)

Beyond the preview

Go deeper on SBC116.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SBC116.

Explore the full profile